UK’s MHRA approves nogapendekin alfa inbakicept plus BCG in NMIBC
Enrollment complete for phase 3 UTOPIA trial in LG-IR-NMIBC
Zelenectide pevedotin plus pembrolizumab shows promising anti-tumor activity in mUC
FDA and EMA authorize phase 3 trial of masitinib for mCRPC
